Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

SLDB

SLDB News

Newswire

09:45

Solid Biosciences shares surge 14.07% intraday after FDA grants rare pediatric designation for SGT-212 and Needham initiates Buy rating with $16 target.

16:24

Solid Biosciences Executives Sell Shares Amid Market Volatility

07:17

Solid Biosciences: Needham initiates coverage with Buy rating and $16 PT.

08:09

Solid Biosciences Receives FDA Designations for SGT-212 Gene Therapy

08:03

Solid Biosciences licenses AAV-SLB101 to Andelyn Biosciences for gene therapy development.

View More

About SLDB

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More